NCT00462943 2021-12-28
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
Teva Branded Pharmaceutical Products R&D, Inc.
M.D. Anderson Cancer Center
Emory University
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Teva Branded Pharmaceutical Products R&D, Inc.